1. Combinatorial Cancer Immunotherapies.
- Author
-
Hellmann MD, Friedman CF, and Wolchok JD
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Combined Modality Therapy, Costimulatory and Inhibitory T-Cell Receptors agonists, Costimulatory and Inhibitory T-Cell Receptors antagonists & inhibitors, Humans, Mice, Molecular Targeted Therapy, Oncolytic Viruses immunology, T-Lymphocytes physiology, Cell Cycle Checkpoints immunology, Costimulatory and Inhibitory T-Cell Receptors therapeutic use, Immunotherapy, Neoplasms therapy, T-Lymphocytes immunology, Tumor Microenvironment immunology
- Abstract
T cell checkpoint blockade therapies are revolutionizing the treatment of patients with cancer. Highlighted by the recent success of PD-1 plus CTLA-4 blockade in patients with melanomas, synergistic immunotherapy combinations of modalities represent an important opportunity to improve responses and outcomes for patients. We review the rationale and experience with T cell checkpoint blockade in combination with targeting of other coinhibitory or costimulatory checkpoints, immunomodulatory molecules in the tumor microenvironment, and other anticancer modalities such as vaccines, chemotherapy, and radiation., (© 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF